Doctor of Osteopathy Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Kelly Carver

Hematology Panama City, FL Doctor of Osteopathy

NPI 1235549544 CMS profile 5690064

2100 State Ave, Panama City, FL 32405

Open in the dashboard

General payments

$5,979

313 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Kelly Carver of Panama City, FL is reported in the CMS Open Payments database as having received $5,979 across 313 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 53rd percentile of Hematology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $183 4
2023 General $297 10
2022 General $3,158 157
2021 General $1,563 99
2020 General $366 20
2019 General $412 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kelly Carver
  • Hematology median
  • Middle half of Hematology
  • National median

In program year 2025, general payments to Kelly Carver were reported at $0. Among 733 Hematology profiles paid that year, the median was $1,155 and the middle half received between $135 and $8,023.

Show as a table
Year Kelly Carver Hematology median Middle half National median
2019 $412 $1,012 $122–$9,834 $163
2020 $366 $1,475 $115–$9,198 $114
2021 $1,563 $1,470 $125–$7,444 $132
2022 $3,158 $1,371 $139–$8,471 $149
2023 $297 $1,295 $147–$11,010 $160
2024 $183 $1,286 $146–$9,230 $164
2025 $0 $1,155 $135–$8,023 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Novartis Pharmaceuticals Corporation $829 22 payments
  2. Amgen Inc. $450 32 payments
  3. Celgene Corporation $411 25 payments
  4. AstraZeneca Pharmaceuticals LP $384 24 payments
  5. Merck Sharp & Dohme Corporation $367 20 payments
  6. Janssen Biotech, Inc. $271 17 payments
  7. GlaxoSmithKline, LLC. $229 7 payments
  8. E.R. Squibb & Sons, L.L.C. $213 13 payments
  9. Genzyme Corporation $201 10 payments
  10. Incyte Corporation $179 9 payments
  11. Other $2,445 134 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $5,411 305 payments
  2. Long term medical supply or device loan $533 6 payments
  3. Education $35 2 payments
Products named General payments · program years 2019–2024
  1. KISQALI $487 10 payments
  2. KEYTRUDA $307 17 payments
  3. REBLOZYL $282 17 payments
  4. LIBTAYO $249 12 payments
  5. COSELA $180 5 payments
  6. Lenvima $172 10 payments
  7. DARZALEX $166 9 payments
  8. Kyprolis $161 10 payments
  9. IMBRUVICA $157 8 payments
  10. OPDIVO $156 9 payments
  11. Other $4,991 279 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

313 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record